<DOC>
	<DOCNO>NCT00110279</DOCNO>
	<brief_summary>Avian influenza ( AI ) , bird flu , recently become major health concern Asia part world . The purpose study test safety immune response new AI vaccine healthy adult . Study hypothesis : Influenza A virus widely distribute nature infect wide variety bird mammal . The direct transmission avian influenza virus bird human recently become major health concern Asia part world , raise concern possible influenza pandemic human . This vaccine evaluate safety , infectivity immunogenicity Live Influenza A vaccine H9N2 ( 6-2 ) AA ca reassortant ( A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca ) , cold-adapted , live attenuate virus vaccine administer intranasally protection human pandemic influenza virus H9N2 subtype .</brief_summary>
	<brief_title>Safety Immune Response Bird Flu Virus Vaccine ( H9N2 ) Healthy Adults ( Study A )</brief_title>
	<detailed_description>AI viruses natural reservoir waterfowl source novel HA NA subtypes introduce human population , potential initiate influenza pandemic . This study evaluate safety immunogenicity live , attenuate , cold-adapted reassortant AI virus vaccine , H9N2 ( 6-2 ) AA ca Reassortant ( A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca ) . Patient participation study least 60 day , patient follow least 42 day vaccination . In study , participant enrol sequentially , high low dose vaccine , one three group . At study entry Day 0 , participant admit hospital order familiarize trial procedure . Blood nasal wash sample collect prior vaccination . On Day 2 , participant physical exam receive one dose vaccine ; vaccine administer nose drop . Participants undergo direct physical examination daily hospital . Nasal wash also collect daily day admission day prior discharge test presence vaccine virus . Participants may discharge hospital 3 consecutive negative viral culture , Day 14 . Additional blood collection occur daily Day 0 Day 7 Day 21 . Participants return follow-up visit 28 32 day 42 46 day receive vaccine . Blood nasal wash collection occur 2 study visit , participant also direct physical exam . Depending immune response first dose vaccine , participant may ask return hospital 1 2 month first vaccination receive additional dose vaccine .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Born 1968 Good general health Available duration trial Clinically significant neurologic , cardiac , pulmonary , hepatic , rheumatologic , autoimmune , renal disease Behavioral , cognitive , psychiatric disease , opinion investigator , affect ability volunteer understand cooperate study Liver , renal , hematologic disease Alcohol drug abuse within 12 month study entry History severe allergic reaction anaphylaxis Current asthma reactive airway disease History GuillainBarre syndrome HIV1 infect Hepatitis C virus infect Positive hepatitis B surface antigen ( HBsAg ) Known immunodeficiency syndrome Use corticosteroid immunosuppressive drug within 30 day study entry . Participants use topical corticosteroid exclude . Live vaccine within 4 week study entry Killed vaccine within 2 week study entry Absence spleen Blood product within 6 month study entry Current smoker Have travel Southern Hemisphere Asia within 30 day prior study entry Have travel cruise ship within 30 day prior study entry Work poultry industry Investigational agent within 60 day prior study entry , currently participate another investigational vaccine drug trial Allergy egg egg product Purified protein derivative ( PPD ) positive ( positive tuberculosis [ TB ] test ) Family member immunodeficiency Other condition , opinion investigator , would affect participant 's participation study Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Bird Flu</keyword>
</DOC>